Drugmakers' Q1 was anemic
at Investor's Business Daily - Thu Apr 24, 5:36PM CDT
Citing R&D and marketing costs, AstraZeneca (AZN) missed EPS estimates with a 17% drop to $1.17. Flat sales of $6.4 bil did beat views. Eli Lilly (LLY) met EPS views of 70 cents, but sales fell 16% to $4.7 bil. Novartis (NVS) EPS slid 3% to $1.28,...
Actavis got a Pfizer
at Investor's Business Daily - Thu Apr 24, 5:36PM CDT
Actavis (ACT) got a Pfizer (PFE) license to start selling a generic form of painkiller Celebrex by Dec. or before, pending FDA OK. Teva (TEVA) and Pfizer reached a similar deal last week. Actavis shares fell 0.4%.
3 Drugs Johnson & Johnson’s Investors Better Know About
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 24, 5:30PM CDT
Johnson & Johnson's sales grew 3.5% during the past year, but only because of big sales growth from a handful of its recently launched drugs. Among these fast-growing new drugs are Johnson's next-generation treatment for diabetes, a new...
Most active New York Stock Exchange-traded stocks
AP - Thu Apr 24, 5:05PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Thu Apr 24, 5:04PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Pfizer to help investors with dividend, buybacks
By The Associated Press - AP - Thu Apr 24, 4:08PM CDT
SHORT HILLS, N.J. (AP) — Pfizer Inc. CEO Ian Read says the drugmaker will keep working to boost shareholder value, with continuing stock buybacks and healthy dividends.
Midday Glance: Pharmaceuticals companies
AP - Thu Apr 24, 12:27PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
AstraZeneca (AZN) Stock Higher Over Pfizer (PFE) Takeover Talk As Earnings Drop
at The Street - Thu Apr 24, 11:31AM CDT
Shares of AstraZeneca (AZN) are up 3.10% to $69.88 as Pfizer (PFE) takeover talk grows even though the biopharmaceutical company reported lower first quarter earnings.
Watch for Shares of Pfizer (PFE) to Approach Support at $30.53
Comtex SmarTrend(R) - Thu Apr 24, 10:43AM CDT
Shares of Pfizer (NYSE
Global Hypertension Drugs Market 2014-2018 with Actelion, AstraZeneca, Boehringer Ingelheim, Novartis, Pfizer, Sanofi Dominating
M2 - Thu Apr 24, 10:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/brq49m/global) has announced the addition of the "Global Hypertension Drugs Market 2014-2018" report to their offering. The Global Hypertension Drugs market is driven by several factors, of which an increase in aging population is one of the major drivers. There is a natural tendency for BP to rise with age due to the reduced elasticity of the arterial system. The promising hypertension drug pipeline is another major driver. The clinical pipeline for hypertension drugs is moderately strong with more emerging therapies. The Global Hypertension Drugs market is experiencing a shift toward combination products, using two or more combination treatments. A combination of hypertension therapy with separate agents or a fixed-dose combination pill lowers BP at a faster pace, helps in reaching the target BP, and decreases adverse effects. Additional benefits may include cost savings and better compliance. Moreover, antihypertensive agents from different classes may balance adverse reactions from each other. For instance, for hypertensive patients with diabetes, the recommended treatment includes diuretics, beta blockers, ACE inhibitors, ARBs, and/or CCBs. The Joint National Committee guidelines have recommended diuretics and ACE inhibitors for recurrent stroke prevention in patients with hypertension; beta blockers, ACE inhibitors, and aldosterone antagonists for hypertensive patients who are post myocardial infarction; and ACE inhibitors and ARBs for hypertensive patients with chronic kidney disease. Further, the report states that the increasing number of patent expirations is one of the main challenges. The patent expiries of major approved drugs will slow down the market growth, as the shift toward lower-priced drugs will lead to a drop in the market valuation for that drug, thereby reducing the overall market value. The Global Hypertension Drugs market can be categorized into eight segments: - Diuretics - ACE Inhibitors - ARBs - CCB - Beta Blockers - Alpha Blockers - Vasodilators - Renin Inhibitors. Key Vendors - Actelion Ltd. - AstraZeneca plc - Boehringer Ingelheim GmbH - Novartis AG - Pfizer Inc. - Sanofi SA Other Prominent Vendors - Bayer AG - Daiichi Sankyo Co. Ltd. - Forest Laboratories Inc. - Merck & Co. Inc. - Takeda Pharmaceutical Co. Ltd. - United Therapeutics Corp. - Valeant Pharmaceuticals International Inc. - XOMA LLC Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Rate of Incidence and Prevalence - Late Stage Pipeline Snapshot - Market Segmentation by Mechanism of Action - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/brq49m/global
Dow Today: Pfizer (PFE) Lower
at The Street - Thu Apr 24, 10:00AM CDT
Holding back the Dow today is Pfizer (NYSE: PFE ), which is lagging the broader Dow index with a 51-cent decline (-1.6%) bringing the stock to $30.41.
Pfizer Hosts Annual Meeting of ShareholdersDeclares 26-Cent Second-Quarter 2014 Dividend
Business Wire - Thu Apr 24, 9:50AM CDT
The board of directors of Pfizer Inc. today declared a 26-cent second-quarter 2014 dividend on the company's common stock, payable June 3, 2014, to shareholders of record at the close of business on May 9, 2014. The second-quarter 2014 cash dividend will be the 302nd consecutive quarterly dividend paid by Pfizer.
Early Glance: Pharmaceuticals companies
AP - Thu Apr 24, 9:33AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Trade-Ideas: Pfizer (PFE) Is Today's "Roof Leaker" Stock
at The Street - Thu Apr 24, 9:12AM CDT
Trade-Ideas LLC identified Pfizer (PFE) as a "roof leaker" (crossing below the 200-day simple moving average on higher than normal relative volume) candidate
Is This Struggling Drugmaker Worth $100 Billion?
Dan Carroll, The Motley Fool - Motley Fool - Thu Apr 24, 8:30AM CDT
The pharmaceutical world got a shock this week from reports that Pfizer had engaged in informal talks with Big Pharma rival AstraZeneca about a possible $100 billion acquisition. AstraZeneca reportedly expressed no interest in the...
Actavis Announces Celebrex® Patent Challenge Settlement
PR Newswire - Thu Apr 24, 8:20AM CDT
Actavis plc (NYSE: ACT) today announced that it has entered into an agreement with Pfizer, Inc. to settle all outstanding patent litigation related to Actavis' generic version of Celebrex® (celecoxib) 50 mg, 100 mg, 200 mg and 400 mg capsules. Celebrex® is indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for the management of acute pain in adults.
Merck, P&G and Other Dividend Stocks You Wish You'd Bought in 2013
at The Street - Thu Apr 24, 5:00AM CDT
I've covered these dividend winners before, but you're not too late to get on board.
European Stocks Rebound Amid M&A, Earnings Headlines
at The Street - Thu Apr 24, 4:56AM CDT
European stocks rebound on Thursday amid mergers and acquisitions excitement.
Will These 3 Dividend Stocks Impress Investors This Earnings Season?
Dan Carroll, The Motley Fool - Motley Fool - Wed Apr 23, 5:30PM CDT
Earnings season already has produced its fair share of surprises, but big pharma's hardly even broken out of the gate so far. However, a trio of major drugmakers are set to release their quarterly results in the next two weeks, and all eyes in the...